Exalpha Biologicals, Inc.

Latest News

Exalpha Biologicals, Inc. is now a US distributor for Nordic-Mubio products

Nordic-MUbio develops and manufactures high quality antibody reagents for use in R&D. All our products are manufactured according to strict ISO 9001 quality guidelines, and our focus is on developing antibodies targetting Cell Adhesion, Nuclear and Cytoskeletal Proteins.

Nordic-MUbio is one of the leading antibody companies developing antibodies for zebrafish research – we currently have over 50 antibodies validated for immunofluorescence in zebrafish.

Learn More

Latest References

Akazawa, Y., et al. "Endoplasmic Reticulum Stress Contributes to Helicobacter Pylori VacA-Induced Apoptosis" PLoS ONE 8(12): e82322

Learn More

Homa, N.J., et al. "Epstein-Barr Virus Induces Global Changes in Cellular mRNA Isoform Usage That Are Important for the Maintenance of Latency" J. Virol., 2013, 87, 12291-12301

Learn More
Exalpha Biologicals, Inc.

SPARC

  • Product Code: X1860P
  • Size: 100 µg
  • Availability: In Stock In Stock
  • Price (USD): $258

Cat #

X1860P		 Quantity:      

Data Sheet

Product Name

SPARC

Synonyms

Secreted Protein Acidic and Rich in Cysteine, SPARC, SPARC-related modular calcium-binding protein 2 [Precursor], Secreted modular calcium-binding protein 2, SMOC-2, Smooth muscle-associated protein 2, SMAP-2

Host/Source

Rabbit

Isotype

IgG

Product Type

Polyclonal Antibody

Reactivity

Human SPARC, may cross react with SPARCL1

Applications

Western Blot, Immunohistochemistry, ELISA

Purification

Ammonium Sulfate Precipitation

Size

100 µg

Price (USD)

$258

Background

SPARC is a key factor in cell-matrix interactions and possibly tumour aggressiveness. The SPARC gene, which encodes a multifunctional glycoprotein with roles in tissue development, remodelling and fibrosis. A regulator of cell-extracellular matrix (ECM) interactions, SPARC represents a major factor in the ECM remodelling occurring during tumour invasion. in silico analysis reveals 4 UTR-SNPs located in the 3 -UTR of the SPARC gene, corresponding to 1474 g a, 1551 g c, 1922 t g and 2072 c t changes, which are significantly associated with tumoral state of the tissue. Of all hits, the 2072 SPARC polymorphism had the best association with cancer. SPARC therefore is a gene involved in a number of diseases including rheumatoid arthritis, scleroderma, tumor development and metastasis. SPARC variants have been detected in tumour samples of patients with acute myeloblastic leukemia (AML).

Immunogen

Synthetic peptide derived from the human SPARC protein.

Positive Control

Antibody tested on mouse heart lysate

Formulation

Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Target Molecular Weight

49674

Product Image

Image Legend

Detection of endogenous SPARC in mouse heart lysate using X1860P (5 ug/ml) and anti-rabbit HRP (1:75k) and using Pierce?s Super Signal West Femto.

Database Links:

SwissProtP09486Human

References

1. Shi Q, et al. 'Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.' Oncogene. 2007 Jan 8; [Epub ahead of print] PMID: 17213807

2. Aouacheria A, et al. 'In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions.' BMC Genomics. 2007 Jan 3;8(1):2 [Epub ahead of print] PMID: 17201911

3. Xue LY, et al. 'Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma.'
BMC Cancer. 2006 Dec 22;6(1):296 [Epub ahead of print] PMID: 17187659

4. Arp HP, et al. 'Predicting the partitioning behavior of various highly fluorinated compounds.' Environ Sci Technol. 2006 Dec 1;40(23):7298-304. PMID: 17180981

5. Kelly KA, et al. 'SPARC is a VCAM-1 counter-ligand that mediates leukocyte transmigration.' J Leukoc Biol. 2006 Dec 18; [Epub ahead of print]

6. Markovic, S., et al. 'Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: A translational study of NCCTG trial N057E.' J. Clin. Oncol. 2010, Vol. 28, No. 15, 8578

7. Weiss, G.J., et al. 'Molecular characterization of interdigitating dendritic cell sarcoma.' Rare Tumors, 2010, 2:e50

8. Alonso, E.N., et al. ?Genes Related to Suppression of Malignant Phenotype Induced by Maitake D-Fraction in Breast Cancer Cells.? J. Med. Food., 16, 602-617 (2013).